Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 3:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 573 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allergic Disease Clear all
Not yet recruiting Not applicable Interventional

Evaluation of Hypersensitivity Reactions to Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh in Shoulder Surgery

NCT07573202
View directory record Official record
Conditions
Hypersensitivity Reactions, Allergic Contact Dermatitis
Interventions
Silk fibroin (SYLKE), 2-octyl cyanoacrylate mesh (Dermabond PRINEO)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

NCT01287364
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Mission Viejo, California • San Diego, California • North Dartmouth, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Jul 24, 2026, 3:03 AM EDT
Completed No phase listed Observational

Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections

NCT00405899
View directory record Official record
Conditions
Allergy, Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2010 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Phase 1 Interventional Results available

Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma

NCT00434421
View directory record Official record
Conditions
Allergy, Asthma
Interventions
Glycerinated German cockroach allergenic extract, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Not applicable Interventional Results available

Immune Dysfunction in Allergic Asthma

NCT00189228
View directory record Official record
Conditions
Asthma
Interventions
Xolair
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Jul 24, 2026, 3:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Nasal Samples of Seasonal Allergic Rhinitics

NCT04670627
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Rhinovirus
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

NCT00570492
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 8 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
50
States / cities
Oxford, Alabama • Little Rock, Arkansas • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects

NCT00620230
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
NVP-VAK694
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
North Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2010 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01279057
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Jul 24, 2026, 3:03 AM EDT
Recruiting Phase 3 Interventional

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

NCT07309432
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
REGN5713, REGN5715, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Andover, Massachusetts • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 24, 2026, 3:03 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study to Evaluate Ear Acupressure Effects in Treating Seasonal Allergic Rhinitis

NCT01921348
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
acupressure pellets
Device
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy

NCT01353079
View directory record Official record
Conditions
Allergy
Interventions
Short Ragweed Pollen Allergenic Extract, Placebo
Biological
Lead sponsor
Greer Laboratories
Industry
Eligibility
18 Years to 55 Years
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Warrenton, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements

NCT00466596
View directory record Official record
Conditions
Allergic Rhinitis, Mild Asthma
Interventions
Gamma Tocopherol
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04753697
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With & Without Allergies

NCT00617110
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
live attenuated influenza virus (LAIV) with clean air, LAIV and diesel exhaust particles
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Phase 3 Interventional

A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

NCT01673659
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone furoate, Nasonex Nasal Spray, Placebo nasal spray
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Jul 24, 2026, 3:03 AM EDT
Completed No phase listed Observational

Screening Protocol for Genetic Diseases of Allergic Inflammation

NCT00852943
View directory record Official record
Conditions
Eosinophilic Disease, Immune Deficiency, HaTS, Urticaria Anaphylaxis, Elevated IgE Level
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

NCT00634608
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions
Health Information Prescription
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Jul 24, 2026, 3:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study

NCT06623799
View directory record Official record
Conditions
Mental Health Conditions, Allergic
Interventions
Not listed
Lead sponsor
QHSLab, Inc.
Industry
Eligibility
4 Years to 100 Years
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Phase 1 Interventional

Sulforaphane Supplementation in Atopic Asthmatics

NCT01845493
View directory record Official record
Conditions
Asthma
Interventions
Alpha Sprout Homogenate, Sulforaphane Homogenate
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Jul 24, 2026, 3:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Reactions in Contact Dermatitis Affected Skin

NCT01546298
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Patch tests
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Jul 24, 2026, 3:03 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial

NCT00745849
View directory record Official record
Conditions
Vasomotor Rhinitis
Interventions
esomeprazole, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 24, 2026, 3:03 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

University of Virginia Natural History Study

NCT04896138
View directory record Official record
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Diseases, Hypersensitivity Pneumonitis, Idiopathic Interstitial Pneumonias
Interventions
Interstitial Lung Disease
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2035
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 24, 2026, 3:03 AM EDT
Recruiting Phase 4 Interventional

Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

NCT06834165
View directory record Official record
Conditions
Allergic Reactions
Interventions
Neffy, Adrenaline
Drug
Lead sponsor
ARS Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
La Jolla, California • Washington D.C., District of Columbia • Glenview, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 24, 2026, 3:03 AM EDT